GLMD (Galmed Pharmaceuticals) Stock Based Compensation: $0.55 Mil (TTM As of Dec. 2025)


GLMD Galmed Pharmaceuticals Ltd GLMD
27 GF Score
Price $0.57
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals Stock Based Compensation?

Galmed Pharmaceuticals GLMD -11.95% 27 Stock Based Compensation is $0.55 Mil as of Dec. 2025. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

Galmed Pharmaceuticals's Stock Based Compensation for the three months ended in Dec. 2025 was $0.24 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.55 Mil.

Galmed Pharmaceuticals Stock Based Compensation Related Terms

Galmed Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals Stock Based Compensation Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 1.30 0.89 0.53 0.55

Galmed Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.10 0.10 0.11 0.24
GLMD
27GF Score
Galmed Pharmaceuticals Ltd GLMD
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55 Mil.

What does a Stock Based Compensation of $0.55 Mil mean?
Galmed Pharmaceuticals (GLMD) has a Stock Based Compensation of $0.55 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Galmed Pharmaceuticals and its competitors.
Is Galmed Pharmaceuticals' Stock Based Compensation too high?
Galmed Pharmaceuticals' current Stock Based Compensation is $0.55 Mil. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' Stock Based Compensation compare to FBLG and SXTP?
Galmed Pharmaceuticals' Stock Based Compensation of $0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Galmed Pharmaceuticals and its competitors. Galmed Pharmaceuticals's current Stock Based Compensation is $0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current Stock Based Compensation of $0.55 Mil. The current Stock Based Compensation is $0.55 Mil. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current Stock Based Compensation is $0.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score

Get the complete analysis for GLMD

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price